Raparelli V, Elharram M, Moura CS, et al. - Because newer glucose-lowering agents have been shown to be cardioprotective in randomized, controlled trials largely consisting of male participants, researchers investigated sex differences in the cardiovascular effectiveness and safety of sodium-glucose-like transport-2 inhibitors (SGLT-2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors, started as second-line agents compared with sulfonylureas (reference-group) among adults with type 2 diabetes mellitus not controlled with metformin. Eligible participants had no previous history of insulin use. The investigators analyzed American adults with type 2 diabetes mellitus and newly dispensed sulfonylureas, SGLT-2i, GLP-1RA, or dipeptidyl peptidase-4 inhibitors. Findings revealed a lower risk of cardiovascular events in relation to newer glucose-lowering drugs vs sulfonylureas, with greater effectiveness of GLP-1RA seen in women vs men. Overall, newer glucose-lowering agents seemed safe, and a better safety profile was reported for SGLT-2i vs GLP-1RA, irrespective of sex.